Chinese researchers recruited 71,783 adults with type 2 diabetes and found that those who used pioglitazone had a 39% lower risk for myocardial infarction and a nonsignificant reduction in heart failure risk, compared with nonusers of pioglitazone. The findings in the Journal of Diabetes revealed that the pioglitazone group also had lower incidence rates for MI, heart failure and stroke than the non-pioglitazone group.
Study links pioglitazone to reduced MI risk in diabetes
Sign up for DiabetesPro SmartBrief
News for diabetes health professionals
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.